MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Cost of Revenue 2011-2026 | ZYXI
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.4 M | 38.4 M | 32 M | 27.3 M | 17.4 M | 8.81 M | 6.04 M | 4.82 M | 3.52 M | 4.94 M | 4.96 M | 8.14 M | 8.77 M | 7.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.4 M | 3.52 M | 15.1 M |
Quarterly Cost of Revenue Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.28 M | 7.06 M | 8.37 M | - | 10.2 M | 9.97 M | 9.3 M | - | 9.55 M | 9.27 M | 9.27 M | - | 8.39 M | 7.3 M | 6.92 M | - | 6.84 M | 7.27 M | 5.89 M | - | 4.3 M | 4.06 M | 3.4 M | - | 2.26 M | 1.95 M | 1.78 M | - | 1.64 M | 1.33 M | 1.24 M | 4.54 M | 3.88 M | 3.11 M | 2.95 M | 2.4 M | 3 M | 3.44 M | 3.83 M | - | 950 K | 1.17 M | 1.24 M | - | - | - | 997 K | - | 1.55 M | 1.88 M | 2.19 M | - | 2.22 M | 1.79 M | 1.81 M | - | 1.94 M | 1.73 M | 1.44 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 950 K | 4.24 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
45.4 M | $ 31.65 | -5.55 % | $ 1.4 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
574 M | $ 43.45 | 1.31 % | $ 1.34 B | USA |
 |
Abiomed
ABMD
|
162 M | - | - | $ 17.2 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 9.76 | 1.99 % | $ 701 M |  Israel |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.92 | 12.33 % | $ 136 M | USA |
 |
Alphatec Holdings
ATEC
|
187 M | $ 17.97 | -20.68 % | $ 2.57 B | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 322.91 | -0.16 % | $ 9.11 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 53.33 | -2.07 % | $ 7.95 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
5.26 B | $ 95.53 | -2.13 % | $ 141 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.1 | 11.41 % | $ 153 M |  France |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 124.29 | -1.27 % | $ 216 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 13.09 | -3.61 % | $ 1.01 B | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.49 | 29.56 % | $ 24 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 28.66 | -0.49 % | $ 242 M | USA |
 |
InMode Ltd.
INMD
|
77.8 M | $ 14.49 | 0.35 % | $ 1.15 B | Israel |
 |
Pulmonx Corporation
LUNG
|
21.8 M | $ 2.0 | -2.21 % | $ 78.2 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 171.78 | -0.58 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.88 | -0.46 % | $ 90.4 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 97.57 | -1.39 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
56.1 M | $ 20.12 | 9.89 % | $ 464 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 15.66 | 4.96 % | $ 423 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Myomo
MYO
|
5.3 M | $ 0.99 | 0.29 % | $ 6.98 M | USA |
 |
Globus Medical
GMED
|
1.04 B | $ 91.33 | -3.28 % | $ 12.4 B | USA |